Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson’s Disease by Sheu, Jau‐jiuan et al.
Association between Anticholinergic Medication Use and
Risk of Dementia among Patients with Parkinson’s
Disease
Jau-Jiuan Sheu,1,2 Meng-Ting Tsai,3 Steven R. Erickson,4 and Chung-Hsuen Wu5*
1Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan; 2Department of Neurology,
School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Medical Department,
Sanofi, Taipei, Taiwan; 4Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann
Arbor, Michigan; 5School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
STUDY OBJECTIVES To evaluate the association between anticholinergic medication use, categorized by
anticholinergic cognitive burden (primary objective) and cumulative dose (secondary objective),
and the risk of developing dementia among patients with Parkinson’s disease.
DESIGN Retrospective cohort study with an active comparator design.
DATA SOURCE National Health Insurance Research Database in Taiwan (2001–2011).
PATIENTS A total of 1232 adults with Parkinson’s disease who were diagnosed between 2002 and 2004
and taking at least one antiparkinson medication during this period were included. Of these
patients, 694 were exposed to anticholinergic medications categorized as mild (reference group),
and 538 were exposed to anticholinergic medications categorized as moderate or severe (exposure
group).
MEASUREMENTS AND MAIN RESULTS Exposure to different types of anticholinergic medications was catego-
rized by using the Anticholinergic Cognitive Burden (ACB) scale, and cumulative doses of anti-
cholinergic medications were measured by using the cumulative minimum doses (cMD) method.
Associations between anticholinergic medication use and risk of dementia were assessed by multi-
variable Cox proportional hazards models. The type of anticholinergics used (moderate or severe vs
mild ACB) was not significantly associated with an increased risk of developing dementia (hazard
ratio [HR] 0.97, 95% confidence interval [CI] 0.72–1.27). After adjusting for confounders, a high
cumulative dose of anticholinergic drug (> 1095 cumulative minimum doses [cMDs]) was found to
be significantly associated with an increased risk of developing dementia when compared with a
low cumulative dose of anticholinergic drug (≤ 90 cMDs) (HR 3.06, 95% CI 1.35–6.97).
CONCLUSION Among patients with Parkinson’s disease in Taiwan, those with a high cumulative dose of
anticholinergics had an increased risk of being diagnosed with dementia. Physicians should consider
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prescribing the lowest therapeutic dose of anticholinergic medication when making treatment deci-
sions for patients with Parkinson’s disease.
KEY WORDS Parkinson’s disease, anticholinergic drugs, dementia, dose, National Health Insurance
Research Database.
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Dementia is a debilitating condition that
greatly impairs physical and mental function
among the aging population.1, 2 Patients with
Parkinson’s disease are more likely to develop
dementia when compared to healthy individu-
als.3, 4 Previous studies have reported that cog-
nitive decline is common among patients with
Parkinson’s disease.5, 6 In the early stage of
Parkinson’s disease, the prevalence of mild cog-
nitive decline can reach 25%.3, 4 About 40% of
patients in the late stage of Parkinson’s disease
will eventually develop dementia.3
In addition to levodopa, patients with Parkin-
son’s disease are often prescribed anticholinergic
medication for the treatment of motor symp-
toms.7, 8 Despite commonly reported adverse
effects, anticholinergics, which act on postsynap-
tic receptors for neurotransmitters in the stria-
tum that affect motor activity, are usually
considered first-line treatment for patients with
severe tremor when compared to other drug
classes such as dopamine agonists, amantadine,
monoamine oxidase type B inhibitors, and cate-
chol-O-methyltransferase inhibitors.7 In addition,
anticholinergics are commonly prescribed to
treat symptoms of urinary dysfunction such as
overactive bladder, which often occurs in the
late stage of the disease.9, 10 As a result of expo-
sure to anticholinergics, patients often experi-
ence discomfort from adverse effects such as
drowsiness, sedation, or a decline in cognitive
function.7, 8
Previous studies have shown a link between
anticholinergic medication use and an increased
risk of cognitive impairment.11–13 Although cog-
nitive decline induced by anticholinergics was
often considered to be short term and reversible,
recent studies have raised the concern about the
potential link between anticholinergic medica-
tion use and an increased risk of a long-term
cognitive decline such as dementia.13–15 For
example, a recent case-control study conducted
in the United Kingdom found an association
between anticholinergic use and the risk of
dementia among older adults.15
Whether taking anticholinergic drug use is
associated with long-term and irreversible
cognitive impairment such as dementia among
patients with Parkinson’s disease remains
unknown. Previous studies have shown that
older people taking high cumulative doses of
anticholinergics have an increased risk of
dementia.13, 16, 17 However, the association
between the dosage prescribed and development
of dementia in patients with Parkinson’s disease
remains unclear. The fact that dementia is preva-
lent among patients with Parkinson’s disease and
the use of anticholinergics is common, further
investigation to evaluate the association between
anticholinergic medication use and the risk of
dementia is necessary.
Therefore, the purpose of this study was to
evaluate the association between anticholinergic
medication use and the risk of dementia among
patients with Parkinson’s disease. The primary
aim was to evaluate the association between the
type of anticholinergics prescribed and the risk
of dementia. The type of anticholinergics pre-
scribed was categorized by the burden of the
anticholinergic effect of each drug. We hypothe-
sized that among patients with Parkinson’s dis-
ease, taking a drug with a high burden of the
anticholinergic effect would be associated with
an increased risk of dementia compared to tak-
ing a drug with a low burden of the anticholin-
ergic effect. The secondary aim was to evaluate
the association between the cumulative dose
effect of anticholinergics and the risk of demen-
tia. We hypothesized that a high cumulative
dose of anticholinergic drug use would be asso-
ciated with an increased risk of dementia com-
pared to a low cumulative dose of
anticholinergic drug use.
Methods
Data Source
This study was conducted using the National
Health Insurance Research Database (NHIRD),
which is maintained by the Bureau of National
Health Insurance of Taiwan and managed by the
National Health Research Institute (NHRI).18
Since 1995, a single-payer National Health
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Insurance (NHI) program has been implemented
in Taiwan, and up to 99.9% of 23 million Tai-
wanese residents are enrolled.19 In the NHI pro-
gram, health records of all beneficiaries are
recorded in the NHIRD, which is a de-identified,
administrative claims database that contains ben-
eficiaries’ demographics, diagnosis, inpatient and
outpatient procedures, ambulatory care records,
prescription drugs, and enrollment informa-
tion.18
This study was conducted using three cohorts
(2000, 2005, 2010) of the Longitudinal Health
Insurance Database (LHID), providing an 11-
year observation period from January 1, 2001, to
December 31, 2011. Each cohort consists of 1
million Taiwanese beneficiaries randomly
selected from the NHIRD.19 For example, all of
the claims data of the 1 million beneficiaries
drawn in 2010 were extracted and obtained from
NHIRD from 2001 to 2011. In the end, all
claims data of the 3 million beneficiaries were
obtained for up to 11 years.
Study Design and Patient Population
This is a retrospective cohort study. The study
population consisted of patients with Parkinson’s
disease. Patients were eligible to be included in
the study if they were aged 18 years or older
between January 1, 2002, and December 31,
2004 (the enrollment period), and had at least
two outpatient visits or one inpatient visit dur-
ing which they were diagnosed with Parkinson’s
disease. The International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-
9-CM) code was used to identify the study pop-
ulation. Patients were included if the first three
digits of the ICD-9-CM code was 332 (Parkin-
son’s disease). The disease was required to be
diagnosed by a neurologist to increase validity.
To further ensure the validity of the diagnosis,
all patients with Parkinson’s disease were
required to be taking at least one antiparkinson
medication during the enrollment period.
The Anticholinergic Cognitive Burden (ACB)
scale20, 21 was used to identify all anticholinergic
medications assessed in this study. The name of
each drug on the ACB scale is provided in
Table 1. The ACB Scale categorizes each drug
into one of three groups: mild, moderate, or sev-
ere based on the anticholinergic activity associ-
ated with negative cognitive effects including
delirium, mild cognitive impairment, dementia,
or cognitive decline.20, 21 For example, drugs
with possible anticholinergic effects but without
clinically relevant negative cognitive effects are
labeled as mild. In contrast, drugs with clinically
relevant cognitive anticholinergic effects, with
development of delirium, and could pass the
blood-brain barrier are labeled as moderate or
severe.20 We chose to use the ACB scale because
it is the most frequently used, validated, expert-
based anticholinergic scale for assessing negative
cognitive effects.22
The new drug user design for the use of anti-
cholinergics was implemented in this study. The
date of the first anticholinergic medication
observed during the enrollment period was
defined as the index date. To identify patients
who were new users of anticholinergic medica-
tion treatment, we excluded patients receiving
any anticholinergic medication treatment within
Table 1. Anticholinergic Cognitive Burden Scale Scoring
of Drugs
Score 1 (Mild) Score 2 (Moderate) Score 3 (Severe)
Alprazolam Amantadine Amitriptyline
Atenolol Belladonna
alkaloids
Amoxapine
Brompheniramine
maleate
Carbamazepine Benztropine
Bupropion
hydrochloride
Cyclobenzaprine Carbinoxamine
Captopril Cyproheptadine Chlorpheniramine
Chlorthalidone Loxapine Clemastine
Cimetidine
hydrochloride
Meperidine Clomipramine
Clorazepate Methotrimeprazine Clozapine
Codeine Molindone Darifenacin
Colchicine Oxcarbazepine Desipramine
Diazepam Pimozide Dicyclomine
Digoxin Dimenhydrinate
Dipyridamole Diphenhydramine
Disopyramide
phosphate
Doxepin
Fentanyl Flavoxate
Isosorbide Hydroxyzine
Loperamide Imipramine
Metoprolol Meclizine
Morphine Nortriptyline
Nifedipine Olanzapine
Prednisone Orphenadrine
Quinidine Oxybutynin
Risperidone Paroxetine
Theophylline Perphenazine
Trazodone Procyclidine
Triamterene Promethazine
Quetiapine
Scopolamine
Thioridazine
Tolterodine
Trifluoperazine
Trihexyphenidyl
Trimipramine
From Reference.20
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1 year (i.e., the pre-index period) before the
index date. Figure 1 shows the definitions of
each phase during the study period.
We excluded patients if they had ever used
cholinesterase inhibitors or N-methyl-D-aspartate
(NMDA) receptor antagonists (donepezil,
rivastigmine, galantamine, and memantine) dur-
ing the 1-year pre-index period. Cholinesterase
inhibitors or NMDA receptor antagonists are
often used to manage dementia-related symp-
toms or slow the development of symptoms.23
Patients were also excluded if they received mul-
tiple anticholinergic medications on the index
date. In addition, patients were excluded if they
were diagnosed with dementia (ICD-9-CM codes
290.0–290.4, 294.1, 331.0–331.2) and other
cerebral degeneration conditions (ICD-9-CM
codes 331.8–331.9), Huntington’s disease (ICD-
9-CM code 333.4), or Creutzfeldt–Jakob disease
(ICD-9-CM codes 046.11, 046.19) during the 1-
year pre-index period. These diseases are
believed to have a link with dementia.23 Finally,
patients who received treatment for all types of
dementia on the index date were also excluded.
Appendix shows the inclusion and exclusion cri-
teria for the study.
Anticholinergic Exposure
An active comparator pharmacoepidemiology
design was conducted in this study.24 Patients in
both the exposure group (defined later) and the
reference group (defined below) were anti-
cholinergic medication users. Patients not taking
anticholinergics were excluded for two reasons.
First, a nonuser comparison group may intro-
duce bias from confounding by indication.25, 26
An active comparator design increases the simi-
larity in patient characteristics and treatment
indications between the exposure and reference
groups.25, 26 Second, most patients with Parkin-
son’s disease are likely to be prescribed anti-
cholinergics. Given that non-anticholinergic
medication users would have constituted only
0.3% of the population in our study, we decided
to exclude anticholinergic nonusers and adopted
the active comparator design to better evaluate
the association between anticholinergics and
dementia.
To address the primary objective, we evalu-
ated the association between type of anticholin-
ergic, categorized by the burden of the
anticholinergic effect (ACB scale), and risk of
dementia. The exposure group consisted of
patients who were prescribed anticholinergic
medications categorized as moderate or severe
on the ACB scale on the index date. In contrast,
the reference group consisted of patients those
who were prescribed anticholinergic medications
categorized as mild on the ACB scale. We
designed the analysis plan for this objective sim-
ilar to the strategy of an intention-to-treat analy-
sis in a randomized controlled trial and did not
further identify patients who discontinued
Figure 1. The design of the study. Overall study period: 2001/1/1–2011/12/31; Enrollment period: 2002/1/1–2004/12/31;
Index date: the first date of the anticholinergic medication use; Washout period: pre-index date (1-year). Exposure: 3-years
after each index date, calculating cMD, the latest one: 2005/1/1–2007/12/31; Follow up periods: 4-years, the latest one: 2008/
1/1–2011/12/31.
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anticholinergic use or switched to different anti-
cholinergic drugs.
To address the secondary objective, we evalu-
ated the association between the cumulative dose
effect of anticholinergics and the risk of dementia.
Cumulative minimum dose (cMD) was used to
define exposure. We measured the minimum dose
(MD) during the 3-year exposure period based on
the recommended MD of each anticholinergic
drug listed on the ACB scale.20, 21 We adopted the
defined daily dose (DDD) recommended by
World Health Organization to calculate the cMD
of each drug.27 The use of DDD, which measures
the average drug consumption per day to main-
tain effectiveness, allowed us to sum the total
MDs for all anticholinergics that each patient used
during the 3-year exposure period after the index
date. Finally, we calculated cMDs for each user
and categorized the cMDs into five groups: ≤ 90
(reference group), 91–365, 366–730, 731–1095
and > 1095.
Study Outcomes
The outcome was occurrence of dementia,
which was defined as the time to the first diagno-
sis of dementia (ICD-9-CM codes 290.0–290.4,
294.1, 331.0–331.2). The occurrence of dementia
was measured from the end of the 1-year induc-
tion period in the primary objective and was mea-
sured from the end of the 3-year exposure period
in the secondary objective, respectively, to the
date of the dementia diagnosis or to the date of
censoring. The induction period was required to
avoid bias from reverse causation28 and ensure
that the occurrence of dementia was after expo-
sure to anticholinergics because dementia is a dis-
ease with a gradual decline in cognitive function.
Patients were censored at the earliest date of
insurance withdrawal, death, or the end of the 4-
year follow-up period.
Covariates
Covariates—including patient characteristics,
condition-related factors, and medication-related
factors—were considered to be potential con-
founders in the study, and they were measured
in the 1-year pre-index period. Covariates were
selected based on clinical knowledge from prior
studies.13, 21, 29–31 Patient characteristics
included age and sex. Condition-related factors
included duration of Parkinson’s disease before
the index date, hypertension, stroke, hyperc-
holesterolemia, diabetes mellitus, depression,
anxiety, psychotic-related disorder, alcohol-re-
lated disorder, sleep disorder, and head injury.
Concomitant medication-related factors included
drug classes of antihypertensive drugs, antidia-
betic drugs, anticoagulants, antihyperlipidemic
drugs, antidepressants, benzodiazepines, and
antipsychotics. Patients were identified whether
they had ever used the above medications during
the pre-index period.
Statistical Analysis
For both study objectives, v2 tests were used
to compare patient characteristics between
groups. Adjusted multivariable logistic regres-
sion models were used to evaluate the associa-
tion between anticholinergic medication use and
the risk of dementia. Multivariable Cox propor-
tional hazards models were used to estimate the
relative hazards of developing dementia, com-
paring patients with each cMD to the reference
group. SAS proprietary software, release 9.4
(SAS institute Inc., Cary, NC) was used for all
analyses in this study. A two-sided p value
(p<0.05) was used to determine statistical signif-
icance. This study was reviewed and obtained an
exemption from the Taipei Medical University
Joint Institutional Review Board.
Results
Table 2 shows the baseline characteristics of
the study population. Of the three million bene-
ficiaries who were initially examined, 1232 indi-
viduals with Parkinson’s disease who met the
inclusion/exclusion criteria were identified. The
1232 patients were all new anticholinergic medi-
cation users, of whom 538 (43.7%) were in the
exposure group (those who used anticholiner-
gics that were categorized as moderate or severe
on the ACB scale). Compared to patients in the
reference group (those who used anticholiner-
gics categorized as mild on the ACB scale),
patients in the exposure group were less likely
to have hypertension (15.1% vs 23.5%, p<0.01),
stroke (6.7% vs 11.7%, p<0.01), and hyperc-
holesterolemia (7.1% vs 10.5%, p<0.05).
Table 3 shows the results of the multivariable
logistic regression model and Cox proportional
hazards model. About 17.7% of patients taking
anticholinergics with moderate or severe anti-
cholinergic effects developed dementia. After
adjustment for confounders, the type of anti-
cholinergics used was not significantly associated
with a higher likelihood or risk of developing
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dementia (odds ratio [OR] 0.96, 95% confidence
interval [CI] 0.71–1.31; hazard ratio [HR] 0.97,
95% CI 0.72–1.27).
Table 4 shows the association between the
risk of developing dementia and the cumulative
dose effect of anticholinergic drugs among
patients with Parkinson’s disease. A significant
association with an increased occurrence of
dementia was identified in both the logistic
regression model and Cox proportional hazards
model. Among patients with Parkinson’s disease,
use of a high cumulative dose of anticholinergic
drug was significantly associated with a higher
risk of developing dementia when compared to
use of a low cumulative dose of anticholinergic
drug (731–1095 cMD group: OR 2.75 [95% CI
1.02–7.41], HR 2.50 [95% CI 1.01–6.22];
> 1095 cMD group: OR 3.33 [95% CI 1.38–
8.05], HR 3.06 [95% CI 1.35–6.97]).
Discussion
To our knowledge, this is the first large popu-
lation-based study to investigate the association
between anticholinergic drug use and risk of
developing dementia among patients with
Parkinson’s disease. In this retrospective cohort
study of Taiwanese adults with Parkinson’s dis-
eases, although the type of the anticholinergics,
which were classified by the burden of the anti-
cholinergic effect, was not consistently associ-
ated with the risk of developing dementia, the
cumulative dose effect of anticholinergic drugs
was significantly associated with an increased
Table 2. Baseline Characteristics of the Study Population
Anticholinergic Medication Use
Overall
ACB Scale Class:
Mild (Reference
Group)
ACB Scale Class: Moderate Or
Severe (Exposure Group)
(n=1232) (n=694 [56.3%]) (n=538 [43.7%])
Variables No. % No. % No. % p Value
Characteristics
Age (yrs)
< 40 134 10.9 73 10.5 61 11.3 0.18
40–49 88 7.1 40 5.8 48 8.9
50–59 157 12.7 86 12.4 71 13.2
60–69 264 21.4 148 21.3 116 21.6
70–79 424 33.4 243 35.0 181 33.6
≥ 80 165 13.4 104 15.0 61 11.3
Sex
Male 688 55.8 397 57.2 291 54.1 0.26
Female 544 44.2 297 42.8 247 45.9
Duration of Parkinson’s disease (yrs)
0 to < 1 1084 88.0 602 86.7 484 90.0 0.08
1–4 148 12.0 92 13.3 54 10.0
Conditions
Hypertension 244 19.8 163 23.5 81 15.1 < 0.01
Stroke 117 9.5 81 11.7 36 6.7 < 0.01
Hypercholesterolemia 111 9.0 73 10.5 38 7.1 < 0.05
Diabetes mellitus 161 13.1 83 12.0 78 14.5 0.19
Depression 38 3.1 21 3.0 17 3.2 0.89
Anxiety 128 10.4 81 11.7 47 8.7 0.09
Psychotic-related disorder 43 3.5 19 2.7 24 4.5 0.11
Alcohol-related disorder 7 0.6 5 0.7 2 0.4 0.40
Sleep disorder 109 8.6 52 7.5 57 10.6 0.06
Head injury 25 2.0 17 2.4 8 1.5 0.22
Medications
Antihypertensives 120 9.7 74 10.7 46 8.6 0.21
Antidiabetics 44 3.6 23 3.3 21 3.9 0.58
Anticoagulants 45 3.7 30 4.3 15 2.8 0.14
Antihyperlipidemic drugs 17 1.4 10 1.4 7 1.3 0.83
Antidepressants 9 0.7 5 0.7 4 0.7 0.96
Benzodiazepines 92 7.5 61 8.8 31 5.8 < 0.05
Antipsychotics 43 3.5 24 3.5 19 3.5 0.94
ACB = Anticholinergic Cognitive Burden.
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risk of developing dementia. These findings sup-
port the notion that use of anticholinergic medi-
cation is associated with increased risk of
developing dementia among patients with
Parkinson’s disease. This potential risk effect,
however, appears to be derived from a high
cumulative dose of anticholinergics.
Previous studies found an association between
anticholinergic medication use and the risk of
cognitive impairment, cognitive decline, or even
dementia among the general older population.11–
13 Our findings further extend these reports to
focus on a more specific population, patients
with Parkinson’s disease. In addition, our study
found the impact of the cumulative dose effect
on dementia. This finding is consistent with the
results of a study13 that found that the risk of
developing dementia was associated with higher
cumulative anticholinergic exposure in a United
States–based study. In combination with our
findings and findings of previous studies,11–13
our study further confirms the association
between anticholinergic medication use and the
increased risk of developing dementia.
For our primary study objective, we did not
find an association between type of anticholiner-
gics prescribed, categorized by the cognitive bur-
den of the anticholinergic effect of the drug, and
increased risk of developing dementia among
patients with Parkinson’s disease. Although the
patients in the exposure group took anticholin-
ergics with a higher cognitive burden effect, the
effect was not significant enough to result in an
increased risk of developing dementia when
compared to patients in the reference group tak-
ing anticholinergics with a lower cognitive bur-
den effect. Two reasons can potentially explain
this nonsignificant finding. First, we used an
active comparator design so that patients in both
the exposure and reference groups took anti-
cholinergics. The cognitive negative effects from
different anticholinergics may not be significant
enough to make a statistically significant differ-
ence. Second, the nonsignificant finding could
be the result of the fact that the exposure was
measured only on the index date without defin-
ing exposure period.11, 14 One study found that
the risk of dementia increased with greater
Table 3. Association between Risk of Developing Dementia and Anticholinergic Medication Use: Results of the Adjusted
Multivariable Logistic Regression Model and Cox Proportional Hazards Modela
Patients Who
Developed
Dementia Logistic Regression Model Cox Proportional Hazards Model
Variables No. % Odds Ratio (95% CI) Hazard Ratio (95% CI)
Anticholinergic medication use: ACB scale class
Moderate or severe 95 17.7 0.96 (0.71–1.31) 0.97 (0.72–1.27)
Mild 135 19.5 Reference Reference
CI = confidence interval; ACB = Anticholinergic Cognitive Burden.
aAdjusted variables including age, sex, duration of Parkinson’s disease before index date, conditions (hypertension, stroke, hypercholes-
terolemia, diabetes mellitus, depression, anxiety, psychotic-related disorder, alcohol-related disorder, sleep disorder, and head injury), and
medications (antihypertensives, antidiabetics, anticoagulants, antihyperlipidemic drugs, antidepressants, benzodiazepines, and antipsychotics).
Table 4. Association between Risk of Developing Dementia and Cumulative Dose Effect of Anticholinergic Drugs among
Patients with Parkinson’s Disease: Results of the Adjusted Multivariable Logistic Regression Model and Cox Proportional
Hazards Modela
Patients Who
Developed
Dementia Logistic Regression Model Cox Proportional Hazards Model
Variable No. % Odds Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
Cumulative minimum doses
≤ 90 26 13.5 Reference Reference
91–365 60 16.7 1.35 (0.48–3.78) 0.57 1.34 (0.51–3.49) 0.55
366–730 55 24.1 2.37 (0.91–6.19) 0.08 2.28 (0.94–5.54) 0.07
731–1095 33 23.6 2.75 (1.02–7.41) < 0.05 2.50 (1.01–6.22) < 0.05
> 1095 56 18.0 3.33 (1.38–8.05) < 0.01 3.06 (1.35–6.97) < 0.01
CI = confidence interval.
aAdjusted variables including age, sex, duration of Parkinson’s disease before index date, conditions (hypertension, stroke, hypercholes-
terolemia, diabetes mellitus, depression, anxiety, psychotic-related disorder, alcohol-related disorder, sleep disorder, and head injury), and
medications (antihypertensives, antidiabetics, anticoagulants, antihyperlipidemic drugs, antidepressants, benzodiazepines, and antipsychotics).
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exposure to and longer duration of anticholiner-
gics.15 After considering the exposure period
and measuring the cumulative dose in the sec-
ondary study objective, the results became sig-
nificant and consistent with the results reported
in the prospective cohort study among older
adults.13
The actual mechanisms contributing to the
association between anticholinergic medication
use and development of dementia among
patients with Parkinson’s disease are not fully
understood. Patients with Parkinson’s disease
may be vulnerable to the central anticholinergic
effects because of age-related decline in hepatic
and renal drug function.32 Patients with Parkin-
son’s disease may also have cortical cholinergic
deficits caused by the degeneration of projection
fibers from the basal forebrain cholinergic sys-
tem.33 Previous research34 suggested that anti-
cholinergics may be associated with functional
and structural changes in the brain. The
research team found that patients who took anti-
cholinergics had reduced brain glucose metabo-
lism and increased brain atrophy, which was
detrimental to cognition.34 In addition, a neu-
ropathologic study35 found that long-term anti-
cholinergic medication use could be associated
with increased Alzheimer-type pathology such as
the amyloid plaque and neurofibrillary tangles,
which could also contribute to the development
of dementia.
In clinical practice, health care providers need
to be aware that the use of anticholinergic drugs
poses a potential risk factor for developing
dementia among patients with Parkinson’s dis-
ease, especially for users with a high cumulative
dose. It is important to check all medications
administered to patients with Parkinson’s disease
for anticholinergic effects and to use a lower
dose or shorten the treatment period to prevent
an increased risk of dementia. In addition,
physicians should regularly screen patients with
Parkinson’s disease for dementia if patients rou-
tinely take medications with anticholinergic
effects and adjust treatment regimens if there is
evidence of cognitive decline.
Our study has several strengths. A new drug
user design and an active comparator design in
pharmacoepidemiology were used in our study
to evaluate the medication exposure and demen-
tia outcome.24, 36 The two designs significantly
reduced the immortal time bias and bias due to
confounding by indication that often happens in
observational studies.24, 36 In addition, the expo-
sure period after an anticholinergic was started
allowed for the measurement of the cumulative
dose effect of anticholinergics before the onset
of dementia in the follow-up period. This design
reduced bias from reverse causation.24, 36
Finally, our study measured the dose and dura-
tion of anticholinergic use, which significantly
improved the clinical implications of the study
findings.
Despite the strengths, there are limitations to
the study. Our data did not include information
regarding sociodemographic or socioeconomic
variables such as education or family income,
which were plausible confounders. Other factors
such as the smoking, dietary habits, and physical
activity were not included. The residual con-
founding effect from these factors could still
exist. Therefore, only association but not the
causality can be implied. As our study used
health administrative claims data, we did not
have a definitive measure of the disease severity.
Findings from a systematic review and commu-
nity-based studies have shown a link between
the progression of Parkinson’s disease and
increased risk of dementia.37–40 The longer that
patients had Parkinson’s disease, the more likely
they were to develop dementia.37–40 The residual
confounding effect derived from Parkinson’s dis-
ease severity could not be fully eliminated even
though we adjusted for disease duration, which
may potentially serve as a proxy of the disease
severity in the regression model. When compar-
ing the baseline characteristics of the study pop-
ulation, we found significant differences between
the reference and exposure groups in the preva-
lence of hypercholesterolemia, stroke, and
hypertension that was associated with the risk of
dementia. Recent literature has shown that
hypercholesterolemia, stroke, and hypertension
are strong risk factors associated with cognitive
decline or dementia.41, 42 We addressed this
issue by controlling for hyperlipidemia, stroke,
and hypertension in our multivariable regression
model. Several scales other than the ACB scale
have been used to measure anticholinergic bur-
den.43–45 Our results could have been different
if a different scale had been used.43–45 In addi-
tion, misclassification of dementia was possible
because we were unable to obtain neurologic
examinations, cognitive assessment, and labora-
tory data such as brain images and biomarker
information used to diagnose dementia.46
Finally, the study was limited to the population
of Taiwan; thus, results may not necessarily be
generalized to populations other than Tai-
wanese.
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Conclusion
A higher cumulative dose of anticholinergic
drug use was found to be significantly associated
with an increased risk of developing dementia in
this population-based cohort with Parkinson’s
disease. Physicians may consider prescribing
medications that do not exhibit anticholinergic
effects, or, if required, prescribe an anticholiner-
gic starting at the lowest therapeutic dose. Regu-
lar cognitive screening assessments are necessary
for patients with Parkinson’s disease who are
exposed to long-term anticholinergic therapy to
prevent dementia. Future studies investigating
the underlying mechanisms between the use of
anticholinergics and the risk of developing
dementia are warranted.
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Appendix. Study inclusion and exclusion criteria. ID = identification; LHIH = Longitudinal Health
Insurance Database; NMDA = N-methyl-D-aspartate.
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